EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
174 hedge funds and large institutions have $832M invested in Eagle Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 55 increasing their positions, 62 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
174
Holders Change
+4
Holders Change %
+2.35%
% of All Funds
3.99%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.11%
New
24
Increased
55
Reduced
62
Closed
19
Calls
$7.07M
Puts
$6.34M
Net Calls
+$727K
Net Calls Change
+$234K
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$15.6M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$12.9M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
+$6.6M |
| 4 |
CEI
Clark Estates Inc
New York
|
+$2.97M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$2.87M |
Top Sellers
| 1 |
Prudential Financial
Newark,
New Jersey
|
-$10.9M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$8.85M |
| 3 |
First Eagle Investment Management
New York
|
-$5.3M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$4.98M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$3.4M |
